世界卫生组织发布了首份针对丝状病毒病的综合临床管理指南，涵盖所有类型的埃博拉和马尔堡病毒[1]。该指南包含16项循证建议，重点强调早期支持性治疗对改善患者存活率和健康结果的重要性[1]。指南涵盖的内容包括优先临床实验室检测、脱水治疗、休克管理、抗生素治疗和患者随访等关键领域[1]。
埃博拉和马尔堡病的病死率范围从25%到90%[1]。自1967年马尔堡病毒首次发现以来，非洲已报告72次埃博拉和马尔堡病疫情[1]。当前，对于马尔堡病毒病、邦迪布焦病毒病和苏丹病毒病，尚无许可的疫苗和治疗方法可用[1]。这份指南是针对刚果民主共和国正在经历的邦迪布焦病毒疫情而发布的[1]。
世界卫生组织总干事Tedros Adhanom Ghebreyesus表示："这些新指南是WHO如何利用科学在疫情和卫生紧急情况期间更好地保护和照顾人民的完美例证"[1]。
The World Health Organization has issued its inaugural comprehensive clinical management guidelines for filovirus diseases, encompassing all types of Ebola and Marburg virus infections [1]. The guidelines contain 16 evidence-based recommendations that underscore the critical role of early supportive care in improving patient survival rates and health outcomes [1].
The development of these guidelines was prompted by an ongoing Bundibugyo virus outbreak in the Democratic Republic of the Congo [1]. According to WHO Director-General Tedros Adhanom Ghebreyesus, the new guidelines represent "a perfect example of how WHO uses science to better protect and care for people during epidemics and health emergencies" [1]. Currently, there are no licensed vaccines or treatments available for Marburg virus disease, Bundibugyo virus disease, and Sudan virus disease [1].
The recommendations address key clinical interventions including priority clinical laboratory testing, management of dehydration, shock treatment, antibiotic therapy, and patient follow-up [1]. This represents a significant development given the severity of filovirus diseases, which carry case fatality rates ranging from 25 percent to 90 percent [1]. Africa has recorded 72 Ebola and Marburg disease outbreaks since the Marburg virus was first identified in 1967 [1].